On these pages you can check out the latest breast cancer news from BCAC and our member groups. We also provide up-to-date information and links to current breast cancer research and clinical trials. Read latest stories below, or use the filters or the pager below for other stories. Use the form to the right of this to subscribe to our e-News.
BCAC media release - 5 March 2020
It is fantastic news that funding for a vital drug for women with advanced breast cancer, palbociclib (Ibrance), will cover the costs for all those who need it , Libby Burgess, Chair of the Breast Cancer Aotearoa Coalition (BCAC) says.
BCAC media release, 15 January 2020: Breast Cancer Aotearoa Coalition (BCAC) is delighted to hear that Ibrance (palbociclib) will be funded by PHARMAC from 1 April 2020.
BCAC media release, 5 December 2019
Breast Cancer Aotearoa Coalition (BCAC) is delighted to learn that fulvestrant (Faslodex) will be funded by PHARMAC in the New Year, BCAC Chair Libby Burgess says.
Media release, 1 October 2019
BCAC is extremely disappointed to read that access to cancer medicines does not appear to be a priority for New Zealand’s new cancer control agency according to its national director, Diana Sarfati, in a recent interview.
Today (8 August 2019) PHARMAC released a proposal to fund Kadcyla (trastuzumab emtansine, T-DM1) for women with advanced HER2 positive breast cancer.
BCAC media release, 28 July 2019
Breast Cancer Aotearoa Coalition (BCAC) welcomes the announcement that if elected National would set up an independent cancer agency to ensure every New Zealander gets high-quality cancer care and to eliminate post code inequities.
Media Release of the Breast Cancer Aotearoa Coalition and Lung Foundation New Zealand
BCAC and Lung Foundation NZ media release, 3 May...
BCAC and Lung Foundation NZ media release, 30 April 2019
Health advocacy groups and individuals will present strongly worded petitions to Parliament on 7 May demanding proper funding of medicines.
Breast Cancer Aotearoa Coalition media release, 23 April 2019: PHARMAC has refused funding for Kadcyla, an important drug that has recently had a high media and public profile.